2nd Annual Predictive Preclinical Models in Oncology
Challenging Cancer Heterogeneity with Reproducible and Predictive Preclinical Studies
Predictive Preclinical Models in Oncology is designed to highlight the cutting edge in vitro and in vivo preclinical models that allow to more effectively evaluate novel cancer therapeutics as well as to identify predictive biomarkers in early stages of drug development. Case studies and solutions for increasing the reproducibility and predictability of preclinical cancer studies will be presented.
Day 1 | Day 2 | Day 3 | Download Brochure
Monday, June 3
2:00 - 5:00 pm Roadmap for Outsourcing of Preclinical Imaging
Wednesday, June 5
6:00 - 9:00 pm Genetically Engineered Mouse Models versus Patient-Derived Xenograft Models: Comparing Strengths and Limitations
* Separate registration required
Tuesday, June 4
7:45 am Registration and Morning Coffee
8:30 Chairperson’s Opening Remarks
8:50 Application of Complex Animal Models in Oncology Drug Design and Early Development
Norman M. Greenberg, Ph.D., Vice President, Research and Development, MedImmune
One of our goals is to establish and strengthen tied with leading investigators at academic, government, biotechnology and pharmaceutical organizations that have expertise in, and access to, complex and robust in vitro and in vivo models for oncology research. This presentation will focus on select programs that leverage our investment and growing expertise in sophisticated model systems to advance important medicines to unmet medical needs.
9:30 Validation of Animal Models of Cancer: It Takes a Village
Terry A. Van Dyke, Ph.D., Head, Mouse Cancer Genetics Program; Program Director, Cancer Pathways and Mechanisms, National Cancer Institute
10:10 Coffee Break
10:40 Pre-Clinical Mouse Models of Glioma
Eric Holland, M.D., Ph.D., Director, Brain Tumor Center; Vice Chair, Translational Research, Department of Surgery, Emily Tow Jackson Chair in Oncology, Memorial Sloan Kettering Cancer Center.
11:10 Frederick National Laboratory for Cancer Research - New Opportunities.
David Heimbrook, Ph.D., CEO, SAIC-Frederick National Laboratory for Cancer Research
11:40 Utilization of Predictive Champions TumorGraft Models to Guide Oncology Drug Development
David Sidransky, MD, Chairman & Co-Founder, Champions Oncology, Inc.
One of the challenges of oncology drug development is the ability to translate preclinical research into the clinical strategy. By using relevant patient derived xenografts, such as Champions TumorGraft models, oncology drug developers can better guide a compound’s development from the lab to the clinic. Other relevant uses of Champions TumorGraft models are to personalize cancer treatment for patients and facilitate biomarker discovery and validation.
12:10 pm in vivo Complex Chimeric NOG Mice: Model Development and Use for Preclinical Evaluation of Drugs
Jean-François Mirjolet, Ph.D., Technology Director, Oncodesign
Many findings from conventional animal models (i.e. syngeneic or xenogeneic) are not easily translated and do not apply to humans due to the intrinsic differences between species (e.g. immune function). Complex in vivo chimeric mouse models having human immune function and human tumor target cells were developed. This presentation will focus on human immune reconstitution using NOG mice, engraftment of human tumors within this context and tools to evaluate immune mediated antitumor effects.
12:40 pm Session Break
1:30 Plenary Keynote Panel Discussion: Advancing Pharma R&D through Communication & Collaborations: Bio-Connectivity at Work
Karim Dabbagh, Ph.D., Executive Director and Head, External R&D and Innovation Research Units, Pfizer Worldwide R&D
Glen N. Gaulton, Ph.D., Professor, Pathology and Laboratory Medicine; Executive Vice Dean and CSO, Perelman School of Medicine, University of Pennsylvania
Peter Pitts, President and Co-Founder, Center for Medicine in the Public Interest
3:00 Grand Opening of the Exhibit Hall with Poster Viewing
4:00 The Co-Clinical Trial Paradigm: Improving Predictive Value of Preclinical Studies
Dr. Andrew L. Kung, M.D., Ph.D., Director, Pediatric Hematology, Oncology and Stem Cell Transplantation, New York-Presbyterian Morgan Stanley Children’s Hospital/Columbia University Medical Center
Conventional mouse studies are poor predictors of efficacy in human clinical trials. The predictive value of preclinical studies may be improved by utilizing newer models that recapitulate the complexity of human disease, along with response criteria that are better aligned with clinical measures of success. The use of genetically engineered mouse models, patient derived xenografts, and molecular imaging will be reviewed in the context of the co-clinical trial paradigm.
4:30 Panel Discussion: Advancing Preclinical Oncology with Better Science and Better Collaboration
Moderator: Terry A. Van Dyke, Ph.D., Head, Mouse Cancer Genetics Program; Program Director, Cancer Pathways and Mechanisms, National Cancer Institute
Panelists: Speakers of Keynote Session
5:30 Welcome Reception in the Exhibit Hall with Poster Viewing
6:30 Close of Day
Day 1 | Day 2 | Day 3 | Download Brochure